Polymeric micellar delivery reduces kidney distribution and nephrotoxic effects of cyclosporine a after multiple dosing

Journal of Pharmaceutical Sciences

Volumn 97, Issue 5, 2008, Pages 1916-1926

  Aliabadi, Hamidreza Montazeri ^a   Elhasi, Sara ^a   Brocks, Dion R ^a   Lavasanifar, Afsaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cremophor EL; Cyclosporine A; Drug delivery; Nephrotoxicity; Polymeric micelles

Indexed keywords

CREATININE; CREMOPHOR; CYCLOSPORIN A; ELECTROLYTE; POLY(ETHYLENE OXIDE) B POLY(EPSILON CAPROLACTONE); POLYMER; POTASSIUM; UNCLASSIFIED DRUG; UREA; CYCLOSPORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; KIDNEY; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; MALE; MICELLE; MICELLIZATION; NEPHROTOXICITY; NONHUMAN; POTASSIUM BLOOD LEVEL; RAT; UREA BLOOD LEVEL; WEIGHT GAIN; ANIMAL; CHEMISTRY; DRUG EFFECT; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CYCLOSPORINE; KIDNEY; MALE; MICELLES; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 48549085316     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21036     Document Type: Article

References (39)

1. Nishiyama N, Kato Y, Sugiyama Y, Kataoka K. 2001. Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system. Pharm Res 18:1035-1041.
2. Kwon GS, Yokoyama M, Okano T, Sakurai Y, Kataoka K. 1993. Biodistribution of micelle-forming polymer-drug conjugates. Pharmaceut Res 10:970-974.
3. Bogdanov AA, Jr., Martin C, Bogdanova AV, Brady TJ, Weissleder R. 1996. An adduct of cis-diammi-nedichloroplatinum(II) and poly(ethylene glycol)poly(L-lysine)-succinate: Synthesis and cytotoxic properties. Bioconjugate Chem 7:144-149.
4. Park YJ, Lee JY, Chang YS, Jeong JM, Chung JK, Lee MC, Park KB, Lee SJ. 2002. Radioisotope carrying polyethylene oxide-polycaprolactone copolymer micelles for targetable bone imaging. Bioma-terials 23:873-879.
5. Zhang X, Burt HM, Mangold G, Dexter D, Von Hoff D, Mayer L, Hunter WL. 1997. Anti-tumor efficacy and biodistribution of intravenous polymeric micel-lar paclitaxel. Anticancer Drugs 8:696-701.
6. Le Garrec D, Gori S, Luo L, Lessard D, Smith DC, Yessine MA, Ranger M, Leroux JC. 2004. Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: In vitro and in vivo evaluation. J Control Release 99:83-101.
7. Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K. 2003. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 63:8977-8983.
8. Buurman WA, Ruers TJ, Daemen IA, van der Linden CJ, Groenewegen G. 1986. Cyclosporin A inhibits IL 2-driven proliferation of human alloactivated T cells. J Immunol 136:4035-4039.
9. Wish JB. 1986. Immunologic effects of cyclosporine. Transplant Proc 18:15-18.
10. Foxwell BM, Mackie A, Ling V, Ryffel B. 1989. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 36:543-546.
11. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K. 1978. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2:1323-1327.
12. Mihatsch MJ, Thiel G, Basler V, Ryffel B, Land-mann J, von Overbeck J, Zollinger HU. 1985. Morphological patterns in cyclosporine-treated renal transplant recipients. Transplant Proc 17:101-116.
13. Sweny P, Hopper J, Gross M, Varghese Z, Whiting PH, Blair JT, Simpson JG, Davidson RJL, Thomson AW. 1981. Nephrotoxicity of cyclosporine A. Lancet 1:663.
14. Chapman JR, Griffiths D, Harding WGL, Morris PJ. 1985. Reversibility of cyclosporine nephrotoxicity after three months treatment. Lancet 1:128-130.
15. Stores E, Luscher TF, de Groot FG, Koomans HA, Rabelink TJ. 1997. Cyclosporine increases nitric oxide activity in vivo. Hypertension 29:570-575.
16. Tariq M, Morais C, Sobki S, Al Sulaiman M, Al Khader A. 1999. N-Acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats. Nephrol Dial Transplant 14:923-929.
17. Mun KC. 2004. Effect of epigallocatechin gallate on renal function in cyclosporine-induced nephrotoxicity. Transplant Proc 36:2133-2134.
18. Satyanarayana PS, Singh D, Chopra K. 2001. Quer-cetin, a bioflavonoid, protects against oxidative stress-related renal dysfunction by cyclosporine in rats. Methods Find Exp Clin Pharmacol 23:175-181.
19. Satyanarayana PS, Chopra K. 2002. Oxidative stress-mediated renal dysfunction by cyclosporine A in rats: Attenuation by trimetazidine. Ren Fail 24:259-274.
20. Satyanarayana PS, Chopra K. 2002. Selective Angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity. Pharmacol Res 45: 413-420.
21. Aliabadi HM, Elhasi S, Mahmud A, Gulamhusein R, Mahdipoor P, Lavasanifar A. 2007. Encapsulation of hydrophobic drugs in polymeric micelles through co-solvent evaporation: The effect of solvent composition on micellar properties and drug loading. Int J Pharmaceut 329:158-165.
22. Aliabadi HM, Mahmud A, Sharifabadi AD, Lavasanifar A. 2005. Micelles of methoxy poly(ethylene oxide)-b-poly(ε-caprolactone) as vehicles for the solublization and controlled delivery of cyclosporine A. J Controlled Release 104:301-311.
23. Aliabadi HM, Brocks DR, Lavasanifar A. 2005. Polymeric micelles for the solublization and delivery of cyclosporine A: Pharmacokinetics and biodis-tribution. Biomaterials 26:7251-7259.
24. Chimalakonda AP, Shah RB, Mehvar R. 2002. High-performance liquid chromatographic analysis of cyclosporin A in rat blood and liver using a commercially available internal standard. J Chromatogr B: Anal Technol Biomed Life Sci 772:107-114.
25. Aliabadi H, Spencer T, Mahdipoor P, Lavasanifar A, Brocks D. 2006. Insights into the effects of hyperlipoproteinemia on cyclosporine a biodistribution and relationship to renal function. Aaps J 8:E672-681.
26. Yang CW, Ahn HJ, Kim WY, Li C, Jung JY, Yoon SA, Kim YS, Cha JH, Kim J, Bang BK. 2003. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Transplantation 75:309-315.
27. Asai T, Nakatani T, Yamanaka S, Tamada S, Kishi-moto T, Tashiro K, Nakao T, Okamura M, Kim S, Iwao H, Miura K. 2002. Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism. Transplantation 74:784-791.
28. Ishikawa A, Suzuki K, Fujita K. 1999. Mechanisms of cyclosporine-induced nephrotoxicity. Transplant Proc 31:1127-1128.
29. First MR. 2003. Renal function. In: Kaplan LA, Pesce AJ, editors. Clinical chemistry: Theory, analysis, correlation, 4th edition. St. Louis, MO: Mosby Inc. p 483.
30. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF. 2003. Mycophenolate mofetil ameliorates arteriolo-pathy and decreases transforming growth factor-betal in chronic cyclosporine nephrotoxicity. Am J Transplant 3:1550-1559.
31. Zhang X, Jackson JK, Burt HM. 1996. Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharmaceut 132:195-206.
32. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T. 2005. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 93:678-687.
33. Anjaneyulu M, Tirkey N, Chopra K. 2003. Attenuation of cyclosporine-induced renal dysfunction by catechin: Possible antioxidant mechanism. Ren Fail 25:691-707.
34. Hosogai N, Tomita M, Hamada K, Ogawa T, Hirosumi J, Manda T, Mutoh S. 2003. Phosphodiesterase type 5 inhibition ameliorates nephrotoxicity induced by cyclosporin A in spontaneous hypertensive rats. Eur J Pharmacol 477:171-178.
35. Vadiei K, Lopez-Berestein G, Perez-Soler R, Luke DR. 1991. Tissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine. Drug Metab Dispos 19:1147-1151.
36. Choice E, Masin D, Bally MB, Meloche M, Madden TD. 1995. Liposomal cyclosporine. Comparison of drug and lipid carrier pharmacokinetics and biodistribution. Transplantation 60:1006-1011.
37. Fahr A, Holz M, Fricker G. 1995. Liposomal formulations of cyclosporin A: Influence of lipid type and dose on pharmacokinetics. Pharmaceut Res 12:1189-1198.
38. Smeesters C, Giroux L, Vinet B, Arnoux R, Chaland P, Corman J, St-Louis G, Daloze P. 1988. Efficacy of incorporating cyclosporine into liposomes to reduce its nephrotoxicity. Can J Surgery 31:34-36.
39. Freise CE, Liu T, Hong K, Osorio RW, Papahadjo-poulos D, Ferrell L, Ascher NL, Roberts JP. 1994. The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome. Transplantation 57: 928-932.